FDA Grants Atia Vision Approval to Begin U.S. Clinical Trial of OmniVu™ Lens System for Cataract Patients
Atia Vision, Inc., a Shifamed portfolio company, announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a traditional feasibility clinical study of its OmniVu™ Lens System. This novel intraocular lens is designed to restore dynamic range of vision following cataract surgery, going beyond the capabilities of current presbyopia-correcting lenses.